Your browser is no longer supported. Please, upgrade your browser.
SRPT Sarepta Therapeutics, Inc. daily Stock Chart
Sarepta Therapeutics, Inc.
Index- P/E- EPS (ttm)-5.35 Insider Own0.40% Shs Outstand54.82M Perf Week-8.22%
Market Cap2.63B Forward P/E- EPS next Y-1.59 Insider Trans-44.76% Shs Float49.27M Perf Month-21.31%
Income-238.70M PEG- EPS next Q-1.32 Inst Own66.10% Short Float22.90% Perf Quarter102.70%
Sales1.30M P/S2023.28 EPS this Y-53.40% Inst Trans0.16% Short Ratio2.75 Perf Half Y220.94%
Book/sh2.63 P/B18.24 EPS next Y68.80% ROA-109.00% Target Price73.86 Perf Year98.02%
Cash/sh2.25 P/C21.35 EPS next 5Y-0.20% ROE-166.30% 52W Range8.00 - 63.73 Perf YTD24.36%
Dividend- P/FCF- EPS past 5Y- ROI-103.00% 52W High-24.71% Beta1.99
Dividend %- Quick Ratio2.30 Sales past 5Y-46.80% Gross Margin- 52W Low499.75% ATR3.71
Employees270 Current Ratio2.30 Sales Q/Q- Oper. Margin- RSI (14)45.75 Volatility5.07% 5.08%
OptionableYes Debt/Eq0.17 EPS Q/Q-33.40% Profit Margin- Rel Volume0.39 Prev Close49.05
ShortableYes LT Debt/Eq0.08 EarningsOct 18 BMO Payout- Avg Volume4.10M Price47.98
Recom1.80 SMA20-15.29% SMA5016.84% SMA20098.19% Volume1,580,309 Change-2.18%
Oct-18-16Initiated Credit Suisse Outperform $68
Oct-10-16Reiterated Wedbush Outperform $66 → $72
Sep-28-16Reiterated RBC Capital Mkts Outperform $83 → $108
Sep-20-16Reiterated Needham Buy $47 → $81
Sep-19-16Upgrade RBC Capital Mkts Sector Perform → Outperform $5 → $83
Sep-19-16Upgrade Jefferies Underperform → Hold
Sep-19-16Reiterated Robert W. Baird Outperform $23 → $102
Jul-22-16Reiterated Needham Buy $20 → $26
Jun-09-16Upgrade Piper Jaffray Underweight → Neutral
Jun-07-16Upgrade Wedbush Neutral → Outperform $36
Jun-01-16Reiterated Wedbush Outperform $14 → $23
May-03-16Downgrade Leerink Partners Mkt Perform → Underperform
Apr-29-16Downgrade Jefferies Hold → Underperform
Apr-26-16Reiterated RBC Capital Mkts Sector Perform $7.50 → $5
Apr-26-16Reiterated Needham Buy $53 → $20
Apr-26-16Downgrade Sun Trust Rbsn Humphrey Neutral → Reduce
Apr-26-16Downgrade Piper Jaffray Neutral → Underweight
Apr-22-16Reiterated RBC Capital Mkts Sector Perform $14 → $7.50
Mar-23-16Downgrade JMP Securities Mkt Perform → Mkt Underperform
Mar-01-16Reiterated Needham Buy $55 → $53
Oct-21-16 08:00AM  Best And Worst Biotech ETFs Of 2016 Tell A Tale About This Industry
Oct-20-16 10:45AM  Trader Be Nimble, Trader Be Quick
Oct-18-16 04:43PM  Sarepta Muscular Dystrophy Drug Interrupts 5-Day Biotech Slump
11:20AM  Sarepta Therapeutics: If You Approve It They Will Come at
08:59AM  PTC Therapeutics Falls on FDA Denial of DMD Drug Appeal
06:49AM  Coverage initiated on Sarepta Therapeutics by Credit Suisse
Oct-17-16 05:21PM  Sarepta Therapeutics' Greatest Threat: Anthem? at Motley Fool -6.39%
Oct-13-16 11:39AM  Pardon Me, but I Have a Few Things to Say... Seattle Genetics, Biomarin, Sarepta, TG Therapeutics
Oct-12-16 01:22PM  Todays Trending Stocks: Sarepta, Humana, HTG Molecular Diagnostics, and More at Insider Monkey
08:39AM  Biotech Stock Roundup: Alnylam Slumps on Revusiran Update, TESARO Impresses at ESMO
Oct-11-16 03:41PM  Why Sarepta Therapeutics Skyrocketed 131% in September at Motley Fool -6.64%
11:27AM  Health insurers split on coverage of Sareptas Duchenne drug at
Oct-10-16 04:57PM  Sarepta Tumbles After Anthems Refusal (SRPT, ANTM) at Investopedia
11:00AM  Better Buy: Alnylam Pharmaceuticals, Inc. vs. Sarepta Therapeutics, Inc. at Motley Fool
Oct-08-16 02:46PM  New Anthem policy will cost DMD patients $300,000 or more at MarketWatch
Oct-07-16 02:56PM  Anthem says will not cover Sarepta's approved Duchenne drug -6.24%
01:05PM  Why Sarepta Therapeutics, Ralph Lauren, Fifth Third Bancorp, and Two Other Stocks Are in Spotlight on Friday at Insider Monkey
12:36PM  Anthem won't cover first FDA-approved Duchenne drug Reuters
12:10PM  Sarepta Therapeutics (SRPT) Stock Drops, Anthem Says DMD Drug 'Not Medically Necessary'
11:23AM  Sarepta stock down 4.8% after Anthem signals it won't cover new DMD drug at MarketWatch
Oct-06-16 12:08PM  CureDuchenne to Host SareptAssist Webinar on October 11 to Provide an Overview of Sareptas Patient Support Program for Duchenne Families Business Wire
Oct-05-16 03:16PM  Sareptas Exondys 51 Drug May Cost $300,000 (SRPT) at Investopedia
01:27PM  Sarepta's Deal With Summit Could Be More About European Eteplirsen Approval Expectations
11:11AM  Ignore Market Jitters, Let Price Action Be the Guide
10:06AM  Sarepta/Summit Ink Deal for Utrophin Modulator DMD Drugs
09:29AM  Biotech Stock Roundup: Summit Soars on Sarepta Deal, Regeneron Presents Data
09:15AM  Blog Coverage Sarepta Announces Collaboration with Summit Therapeutics Accesswire
08:57AM  Blog Coverage Sarepta Announces Collaboration with Summit Therapeutics
Oct-04-16 06:00PM  Sarepta Inks Key DMD Deal (SRPT) at Investopedia
04:09PM  Sarepta may be the real winner from partnership that lifted Summit Therapeutics stock 50% at MarketWatch
02:23PM  Trending Tickers: SDRL, P, SMMT, SRPT
02:21PM  Sarepta Therapeutics (SRPT) Stock Up on Summit Deal, RBC Bullish
12:12PM  Analyst: Sarepta removes potential competitive threat with $562M deal at
11:34AM  Why Sarepta's Licensing Deal Makes This Drug Maker An "Even More Attractive M&A Candidate" at
11:17AM  Sarepta Therapeutics (SRPT) Stock Gains on Summit Licensing Agreement
11:00AM  DMD Deal With Summit Is 'Low Risk, High Reward' For Sarepta
10:35AM  Summit Therapeutics Skyrockets on Sarepta Deal
09:46AM  Early Movers: Darden Lifts Earnings Forecast; Trinity Biotech Plunges, Yanks FDA Applicaiton at
09:22AM  Summit Therapeutics (SMMT) Stock Spikes on Sarepta Licensing Deal
08:37AM  Sarepta Wins Exclusive License, Collaboration Deal for European Rights To Summit's DMD Drug
07:58AM  Summit Therapeutics stock surges 50% on news of licensing deal with Sarepta at MarketWatch
07:29AM  Summit and Sarepta to collaborate on muscular dystrophy drug
07:07AM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E
07:00AM  Sarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for European Rights to Summits Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy GlobeNewswire
Oct-03-16 08:39AM  6 Best Performing Drug Stocks of September
Oct-02-16 10:05AM  Top 6 Biopharma Gainers of the Past Week at 24/7 Wall St.
09:57AM  Is Sarepta Therapeutics Still a Risky Bet? at Motley Fool
Oct-01-16 09:00AM  'Mad Money' Lightning Round: Buy, Buy, Buy Home Depot
Sep-30-16 07:21PM  Cramer: We've missed the big move on Sarepta Therapeutics at CNBC
04:16PM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Other Events
01:28PM  Biotech stocks have plenty of catalysts around the corner at MarketWatch
12:56PM  Kite, Anavex, G.W. Pharma Help Revive Biotech Sector Chemistry
12:49PM  Shark Bites: Market Responds With 'Deutsche Who?'
10:54AM  One Biotech Crashes, the Other Skyrockets -- Here's Why at Motley Fool
10:28AM  The Crazy Backstory Around Sarepta Therapeutics' Game-Changing Drug Approval at Motley Fool
09:13AM  5 Top Performing Stocks of the Best ETF of Q3
Sep-29-16 12:40PM  Catabasis Skyrockets on Sarepta Partnership
11:34AM  Sarepta announces Duchenne research partnership with Cambridge's Catabasis at
08:00AM  Catabasis Pharmaceuticals and Sarepta Therapeutics Announce a Joint Research Collaboration in Duchenne Muscular Dystrophy Business Wire
Sep-28-16 06:00PM  Sarepta Therapeutics Announces First Patient Dosed in Phase III Clinical Trial of SRP-4045 and SRP-4053 for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping Business Wire +5.31%
04:21PM  Sarepta's Costly Muscular Dystrophy Drug Flirts With Big Pharma M&A
03:14PM  Heres Why These Five Stocks Are Trading Higher Today at Insider Monkey
12:21PM  Better Buy: BioMarin Pharmaceuticals Inc. vs. Sarepta Therapeutics Inc at Motley Fool
11:15AM  Selling Into Strength Can Be a Great Strategic Move
10:26AM  RBC Capital Markets more than doubles Sarepta price target, citing 'potential for real upside' at MarketWatch
10:17AM  Sarepta Therapeutics (SRPT) Stock Climbs, Analysts Bullish on Exondys
10:04AM  Sarepta: 'Yes, We're Aware Our Price Target is $50 Higher Than the Current Price' at
08:03AM  3 Stocks to Avoid in Healthcare at Motley Fool
Sep-27-16 02:47PM  Sareptas Manufacturing Challenge (SRPT) at Investopedia
Sep-26-16 12:43PM  BioMarin Takes Aim at Rival Sarepta (BMRN, SRPT) at Investopedia
09:56AM  Why Wells Fargo, Sarepta, Delphi, UPS, and More Are Making Headlines at Insider Monkey
Sep-25-16 10:00AM  For Traders, Planning Is More Important Than the Plan
Sep-24-16 01:24PM  2 Stocks I'd Never Buy, and 1 I'll Consider at Motley Fool
07:27AM  The Woman Behind Sarepta Therapeutics' Success at Motley Fool
01:00AM  [$$] Sarepta Still Has Upside at
Sep-23-16 06:50PM  Sarpeta Approval Challenged by FDA (SRPT) at Investopedia -5.15%
05:45PM  Sarpeta Raises Offering After FDA Approval (SRPT) at Investopedia
05:29PM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial St
Sep-22-16 06:00PM  Sarepta Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock Business Wire +8.45%
03:22PM  3 Reasons Sarepta Shares Rallied Following News Of $225 Million Offering
01:36PM  Sarepta Announces Offering of Common Stock (SRPT) at Investopedia
12:59PM  Top trades for the 2nd half: BABA, SRPT & more
12:45PM  5 Stocks With Amazon-Like Growth Potential at Motley Fool
11:04AM  I Am One of the Underinvested Bulls Right Now
10:24AM  FDA Commish Says Sarepta's DMD Study Should Be Retracted
09:35AM  How Sarepta Is Cashing In on Its FDA Homerun at 24/7 Wall St.
08:27AM  Rite Aid Corporation, WCI Communities & Other Stocks in Spotlight Following Earnings, M&A News and More at Insider Monkey
07:39AM  [video]Stock Futures Rise as Wall Street Finds Relief in a Patient Fed
Sep-21-16 08:58PM  Sarepta Wins Favorable USPTO Decisions (SRPT) at Investopedia
05:48PM  [$$] Sarepta to Sell Up to $225 Million of Stock at The Wall Street Journal
04:32PM  'Blockbuster Franchises' Spark M&A Fever For Sarepta, Ariad, Biotechs
04:17PM  Sarepta (SRPT) Stock Slides in After-Hours Trading on Public Offering
04:16PM  Sarepta sales slump after company announces $225 million stock offering at MarketWatch
04:00PM  Sarepta Therapeutics Announces Proposed Public Offering of Common Stock Business Wire
02:26PM  Sarepta's New Drug May Make It a Takeover (SRPT) at Investopedia
01:34PM  Sarepta Therapeutics: BioMarin Still Wants a Piece of the Action at
11:58AM  Sarepta to open Andover manufacturing site soon at
11:50AM  Patent Trial And Appeal Board Hands Sarepta Another Big Win
08:39AM  Biotech Stock Roundup: Tobira Soars on Acquisition Deal, FDA Says Yes to Sarepta DMD Drug
08:31AM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. The company's lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development for the treatment of individuals with Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease caused by the absence of dystrophin. It is also developing exon-skipping drugs for the treatment of DMD; and therapeutic candidates for the treatment of infectious diseases, such as influenza, Marburg, and Ebola. The company has a strategic alliance with Charley's Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies; a license agreement with the University of Western Australia for the use of antisense sequences in the treatment of DMD; and a research collaboration agreement with Catabasis Pharmaceuticals, Inc to explore a combination drug treatment approach for DMD. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mahatme SandeshSenior Vice President, CFOOct 17Option Exercise13.9030,000417,00061,532Oct 19 04:22 PM
Mahatme SandeshSenior Vice President, CFOOct 17Sale50.0830,0001,502,50231,532Oct 19 04:22 PM
Ruff ShamimSVP, Regulatory Affairs & QualSep 22Option Exercise13.907,311101,62327,550Sep 30 09:58 PM
Kaye Edward M. MDPresident, CEO & CMOSep 22Option Exercise8.2840,179332,682117,162Sep 26 04:23 PM
Howton David TSVP, General CounselSep 22Option Exercise13.907,00097,30028,453Sep 26 04:19 PM
Ruff ShamimSVP, Regulatory Affairs & QualSep 22Sale60.007,311438,66020,239Sep 30 09:58 PM
Kaye Edward M. MDPresident, CEO & CMOSep 22Sale60.0040,1792,410,74076,983Sep 26 04:23 PM
Howton David TSVP, General CounselSep 22Sale60.007,000420,00021,453Sep 26 04:19 PM
Howton David TSVP, General CounselSep 19Option Exercise13.908,000111,20011,168Sep 21 09:28 PM
Kaye Edward M. MDPresident, CEO & CMOSep 19Option Exercise6.9424,352168,94189,983Sep 21 09:29 PM
Aphale JayantVP, Technical OperationsSep 19Option Exercise4.6235,000161,70036,490Sep 21 09:31 PM
Aphale JayantVP, Technical OperationsSep 19Sale50.0035,0001,750,00011,490Sep 21 09:31 PM
Kaye Edward M. MDPresident, CEO & CMOSep 19Sale50.0024,3521,217,60076,983Sep 21 09:29 PM
Howton David TSVP, General CounselSep 19Sale50.009,304465,2003,168Sep 21 09:28 PM
Kaye Edward M. MDSVP Interim CEO & CMOSep 14Sale30.0024,557736,71076,983Sep 16 04:04 PM
BEHRENS M KATHLEENDirectorMar 16Buy14.5410,000145,43321,855Mar 16 08:15 PM
BEHRENS M KATHLEENDirectorMar 14Buy16.5465,0001,075,276112,166Mar 16 08:15 PM
Barry RichardDirectorMar 14Buy15.6675,0001,174,1853,241,014Mar 16 08:09 PM